Simile Lands $2B Valuation With $200M Series B
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Simile raised a $200 million Series B at a $2 billion valuation, just five months after emerging from stealth with a $100 million Series A led by Index Ventures.
- Greenoaks led the Series B, with Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures also participating.
- CVS Health Ventures is both an investor in the round and one of Simile's marquee customers, tying investor and customer roles in a single deal.
- Simile sells simulated users for marketing and product research — the source likens the concept to 'vibe coding for product mock-ups.'
- Joon Sung Park, a Stanford PhD graduate, founded Simile; his dissertation project 'Smallville' featured AI agents simulating human lives, right down to holding parties.
- The source calls Simile's stated mission of simulating 'all eight billion people on earth, accurately and honestly' preposterous, arguing market research exists precisely because humans are unpredictable.
- Competitor Aaru raised a Series A in December at a reported $1 billion valuation, signaling broad VC appetite for synthetic-user startups.
Why it matters: Simile's jump from a $100 million Series A to a $2 billion Series B valuation in five months shows how aggressively VCs are pricing synthetic-user AI. CVS investing as both backer and marquee customer signals enterprise pull, while the source's open skepticism of the 'simulate all humans' mission highlights the gap between fundraising hype and the unpredictability the product claims to solve.
